Here, we established that the abundant expression of HLA-G on breast cancer cells and its engagement with the atypical KIR family receptor, KIR2DL4, on NK cells suppress ADCC and contribute to breast cancer resistance to trastuzumab. The gene discussed is KIR2DL4; the disease is breast carcinoma.